Previous studies have suggested that the Trp460 allele of the Gly460Trp polymorphism in the ␣-adducin gene is associated with salt sensitivity and primary hypertension. The present study was undertaken to evaluate if the Trp460 allele of this polymorphism is associated with primary hypertension in Scandinavians. To address this issue, 294 patients with primary hypertension and 265 normotensive control subjects from Sweden were examined and genotyped for the Gly460Trp polymorphism using polymerase chain reaction and restriction fragment length polymorphism methods. We then used a population of 80 patients with primary hypertension and 154 normotensive control subjects from Finland to replicate the findings. The frequency of the Trp460 allele was lower in hypertensive patients than in normotensive controls in the Swedish population (17.7% vs 23.0%; P ‫؍‬ 0.03) and in the Finnish population (14.4% vs 19.5%; NS). Therefore we also performed a pooled analysis in
Introduction
Primary hypertension is a multifactorial and polygenic disease 1 with a considerable genetic component. 2 Abnormal renal sodium handling may be involved in the pathogenesis of the disease. 3 It has been shown that the Milan hypertensive rat (MHS) 4 and a subgroup of humans with hypertension have enhanced transmembranic ion transport, an effect possibly involving the cytoskeleton. [5] [6] [7] [8] Genetic differences in renal tubular salt reabsorption could thus contribute to the development of hypertension. [9] [10] [11] [12] [13] [14] Cross-immunisation of cytoskeleton proteins between MHS and the normotensive rat strain (MNS) revealed immunochemical differences in an ␣/␤ heterodimeric protein called adducin. 15 Adducin is thought to interact with the actin cytoskeleton and could thereby be important for cell signalling. 16, 17 Two mutations in the ␣-adducin and the ␤-adducin genes could explain up to 50% of the differ-which the frequency of the Trp460 allele was significantly lower in hypertensive patients than in normotensive controls (17.0% vs 21 ence in blood pressure between the MHS and the MNS. 9 Transfection studies with cDNA from the MHS showed altered ability of adducin to interact with actin and increased maximum velocity of the sodium-potassium pump. 18 In humans, polymorphic markers flanking the ␣-adducin gene have been shown to be associated with primary hypertension in Italians 19 and linkage has been demonstrated between the ␣-adducin locus and primary hypertension in French families. 20 The tryptophane variant of a polymorphism in the ␣-adducin gene which codes for either glycine or tryptophane at codon 460 (Gly460Trp) has been associated with hypertension in Italian, French and Japanese populations. [20] [21] [22] In addition, Italian hypertensive carriers of the Trp460 allele have been shown to be more salt-sensitive 20 and to have a decreased slope of the pressure natriuresis relationship 23 as compared to the Gly460 homozygotes. However, in other studies no association has been found between the Gly460Trp polymorphism and hypertension 24 -26 or sodium metabolism. 25 The present study was undertaken to investigate whether the Trp460 allele of the Gly460Trp poly-morphism in the ␣-adducin gene is associated with primary hypertension, using two Scandinavian casecontrol populations.
Materials and methods

Study subjects
The study subjects were recruited from health care centres in the Skaraborg and Scania regions in southern Sweden and from the Botnia region in western Finland. A total of 294 unrelated patients with primary hypertension and 265 unrelated healthy normotensive control subjects from Sweden were first enrolled in the study. We then used a population of 80 unrelated patients with primary hypertension and 154 unrelated healthy normotensive controls from Finland to replicate the findings. Patients with primary hypertension had either a diagnosis of established primary hypertension before the age of 60 years and were on chronic pharmacological antihypertensive treatment, or had a systolic and diastolic blood pressure above 160/95 mm Hg, respectively, at the time of the study examination and were less than 60 years old. If there was any uncertainty concerning the diagnosis of primary hypertension, the medical records were checked. Subjects with diabetes mellitus, kidney disease, secondary hypertension or any other chronic disease were excluded. The normotensive controls were selected as follows: (1) systolic and diastolic blood pressure р150 mm Hg and р85 mm Hg, respectively; (2) no personal history of elevated blood pressure, diabetes mellitus or any other chronic disease; (3) absence of medication; and (4) no family history of hypertension in first-degree relatives. The clinical characteristics of the study subjects are shown in Table 1 .
The study was approved by the ethics committee of the Medical Faculty of Lund University and all the study participants had given a written informed consent.
Phenotyping
Blood pressure was measured in the supine position after 5 min rest with a sphygmomanometer by specially trained nurses. Height was measured to the nearest centimetre and weight to the nearest 0.1 kg. Body mass index (BMI) was calculated as the ratio of the weight in kg to the square of the height in metres (kg/m 2 ).
Genotyping
Total genomic DNA was extracted from venous blood by standard methods. 27 Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods were created to genotype the study subjects for the Gly460Trp polymorphism. A gene segment surrounding the Gly460Trp polymorphism in the ␣-adducin gene was amplified with PCR using primers '␣-add-460-F' (5′-ACAGAA CTGGCTACCCTTATC) and '␣-add-460mm-R' (5′-TTGGGACTGCTTCCATTCGGCC) of which the latter contains a nucleotide mismatch (underlined) to create a Sau96I recognition site in case of the Gly460 allele sequence. The primers were designed according to the published ␣-adducin cDNA sequence. 28 PCR was performed with 50 ng of genomic DNA in a total volume of 20 l containing 10 pmol of each primer, 2 nmol dNTPs, 0.5 U Taq polymerase (Perkin-Elmer, Foster City, CA, USA) in 1 × PCRbuffer for Taq-polymerase (10 mM Tris HCl pH 8.3; 50 mM KCl; 1.5 mM MgCl 2 ; 0.001% gelatin) (Perkin-Elmer), 1.5% formamide and 1.5 mM MgCl 2 . PCR conditions were as follows: initial denaturation at 94°C for 5 min, followed by 30 cycles of denaturation (94°C for 30 sec), annealing (60°C for 30 sec) and extension (72°C for 30 sec), with the final extension at 72°C for 10 min. The PCR product was digested with 1 U of Sau96I (New England Biolabs, Beverly, MA, USA) for 3 h in 37°C using the buffer recommended by the manufacturer. The fragments were separated on 4.5% multipurpose agarose gel with ethidium bromide and visualised under ultraviolet light.
Statistics
Frequency differences were estimated by 2 -test and differences in continuous variables by t-test and ANOVA or Mann-Whitney and Kruskal-Wallis test depending on whether the variable was normally distributed or not, using a BMDP statistical package (version 1.1). All tests were two sided and a P-value of less than 0.05 was considered statistically significant.
Results
The genotype frequency distributions observed in the Swedish and the Finnish populations were similar to those expected from the allele frequencies according to the Hardy-Weinberg equilibrium.
The frequency of the Trp460 allele was lower in hypertensive patients than in normotensive controls in both the Swedish and the Finnish populations (Table 2 ). Therefore we also performed a pooled analysis of the two populations in which the frequency of the Trp460 allele was significantly lower in hypertensive patients compared to normotensive controls ( Table 2 ). The genotype frequency distributions of the Gly460Trp polymorphism did not significantly differ between hypertensive patients and normotensive controls either in the Swedish or in the Finnish population but approached a significant difference in the pooled material (P = 0.05) ( Table 3 ). The proportion of subjects carrying the Trp-Trp or the Trp-Gly codon 460 genotypes was significantly lower in hypertensive patients than in normotensive controls in the pooled material (31.3% vs 38.2%, P = 0.04). There was no significant difference between carriers of the different codon 460 genotypes (Trp-Trp, n = 24; Trp-Gly, n = 144; and GlyGly, n = 279) among study subjects who were not on antihypertensive medication (n = 447) either for systolic (128 ± 18; 127 ± 15; and 129 ± 17 mm Hg, NS) or for diastolic blood pressure (75.6 ± 12.1; 74.7 ± 9.3 and 75.0 ± 10.4 mm Hg, NS). Except for a ± 10.4 slight difference in diastolic blood pressure in Swedish hypertensive patients and in Finnish hypertensive patients, of whom the majority were on treatment (Table 1) , there was no difference in blood pressure between carriers of the different genotypes in any of the groups studied (Table 3) .
Discussion
The Trp460 allele of the Gly460Trp polymorphism has been suggested to be associated with salt sensitivity and primary hypertension. 20 In the present study, performed in two Scandinavian case-control populations, the frequency of the Trp460 allele was not increased in patients with primary hypertension which is in line with some other recent studies. All, Swedish and Finnish subjects pooled; HT, patients with primary hypertension; NT, healthy control subjects; *P Ͻ 0.05 (ANOVA).
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In contrast, the frequency of the Trp460 allele was significantly lower in hypertensive patients than in normotensive controls in the Swedish study population (P = 0.03) and in the two study populations pooled (P = 0.02). This constitutes strong evidence against a significant role for the Trp460 allele in the pathogenesis of primary hypertension. The size of our pooled Scandinavian material (374 hypertensive patients and 419 normotensive controls) is of the same magnitude as the size of the pooled FrenchItalian material in which the association of the Trp460 allele to primary hypertension was originally described (477 hypertensive patients and 332 normotensive controls). 20 Furthermore, the definition of primary hypertension and the inclusion criteria for controls in our study were very similar to the ones used in both the French 29, 30 and Italian populations 19 studied in the original report. 20 Thus, there are no obvious clinical differences between the subjects used or differences in power between the two studies which could explain the divergent results. The fact that the frequency of the Trp460 allele was significantly lower in hypertensive patients than in normotensive controls in the Swedish population and in the Swedish and Finnish populations pooled, raises the possibility that another variant located within a short genetic distance, elsewhere in the ␣-adducin gene or in another gene nearby, is in linkage disequilibrium with the
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Gly460Trp polymorphism and confers increased susceptibility to hypertension.
In conclusion, our results strongly argues against a pathogenic role of the Trp460 variant in human primary hypertension. The results rather suggest that another variant in linkage disequilibrium with the Gly460Trp polymorphism increases susceptibility for hypertension.
